Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/30/2026 | $144.00 | Neutral → Outperform | Robert W. Baird |
| 5/11/2022 | Mkt Perform → Outperform | William Blair |
Robert W. Baird upgraded Novanta from Neutral to Outperform and set a new price target of $144.00
William Blair upgraded Novanta from Mkt Perform to Outperform
Novanta Inc. (NASDAQ:NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, will release its second quarter 2026 results after the close of U.S. financial markets on Wednesday, August 5, 2026. The Company will host a conference call on Thursday, August 6, 2026, at 8:00 a.m. ET to discuss these results. To access the call, please dial (888) 346-3959 before the scheduled conference call time. Alternatively, the conference call can be accessed online via a live webcast on the Events & Presentations page of the Investors section of the Company’s website at www.novanta.com. A replay of the audio webcast will be available approximately
Novanta Inc. (NASDAQ:NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Robert Buckley, Chief Financial Officer, and Chuck Ravetto, Chief Operating Officer, are scheduled to present at the CJS Securities 26th Annual New Ideas Summer Conference on Thursday, July 9, 2026, in White Plains, NY. About Novanta Novanta is a leading global supplier of core technology solutions that give medical, life science, and advanced industrial original equipment manufacturers a competitive advantage. We combine deep proprietary expertise and competencies in precision medicine, precision manufacturing, robotics and automation
Novanta Inc. ("Novanta" or the "Company") announced today that it has entered into a securities purchase agreement for a private placement of the Company's common shares ("Common Shares") to institutional and other accredited investors that is expected to result in gross proceeds of approximately $300 million to the Company, before placement agent fees and offering expenses. Pursuant to the terms of the securities purchase agreement, the investors agreed to purchase an aggregate of 2,142,857 Common Shares at a purchase price of $140.00 per share. The private placement is expected to close on or about June 11, 2026, subject to satisfaction of customary closing conditions. The offer and s
S-3ASR - NOVANTA INC (0001076930) (Filer)
8-K - NOVANTA INC (0001076930) (Filer)
8-K - NOVANTA INC (0001076930) (Filer)
4 - NOVANTA INC (0001076930) (Issuer)
4 - NOVANTA INC (0001076930) (Issuer)
4 - NOVANTA INC (0001076930) (Issuer)
Novanta Inc. (NASDAQ:NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, will release its second quarter 2026 results after the close of U.S. financial markets on Wednesday, August 5, 2026. The Company will host a conference call on Thursday, August 6, 2026, at 8:00 a.m. ET to discuss these results. To access the call, please dial (888) 346-3959 before the scheduled conference call time. Alternatively, the conference call can be accessed online via a live webcast on the Events & Presentations page of the Investors section of the Company’s website at www.novanta.com. A replay of the audio webcast will be available approximately
Accelerates Novanta's strategic direction, expands portfolio into high-growth minimally invasive surgery segment, and doubles recurring medical consumables revenue Transaction is immediately accretive to Novanta's revenue growth, Adjusted Gross and EBITDA margins, Adjusted Diluted EPS, and Operating Cash Flows Novanta Inc. (NASDAQ:NOVT) ("Novanta" or the "Company"), a trusted technology partner to leading global medical and industrial original equipment manufacturers (OEMs), today announced that it has entered into a definitive agreement to acquire Riverpoint Medical ("Riverpoint Medical" or "Riverpoint"), a category leader in high-growth minimally invasive surgical consumables, from
First Quarter 2026 GAAP Revenue increased 10% to $258 million First Quarter 2026 GAAP Net Income was $21 million, and Adjusted EBITDA increased 14% to $57 million First Quarter 2026 GAAP Diluted EPS was $0.51, and Adjusted Diluted EPS increased 9% to $0.81 Novanta Inc. (NASDAQ:NOVT) ("Novanta" or the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, today reported financial results for the first quarter 2026. Financial Highlights Three Months Ended (In millions, except per share amounts) April 3, March 28, 2026 2025
IDEX Corporation (NYSE:IEX) today announced the appointment of Stephanie ("Steph") Disher and Matthijs Glastra to the company's Board of Directors. The appointments, effective Friday, February 21, 2025, increase the size of the Board from 10 to 12 directors. Ms. Disher will serve on the Board's Nominating and Corporate Governance Committee, and Mr. Glastra will serve on the Board's Audit Committee. Ms. Disher currently serves as Chief Executive Officer of Atmus Filtration Technologies Inc. (NYSE:ATMU), a leader in filtration and media solutions. She has extensive global leadership experience in finance and operations from her time at Atmus, Cummins Inc. and BP, p.l.c. Mr. Glastra currentl
Sends Letter to Masimo Shareholders and Releases 160-Page Investor Presentation Urges Shareholders to Help Deliver Immediate Change by Voting for Both of Politan's Independent and Ideally Qualified Nominees Darlene Solomon and William Jellison on the WHITE Card Shareholders Can Visit www.AdvanceMasimo.com for Further Information Politan Capital Management (together with its affiliates, "Politan"), an 8.9% shareholder of Masimo Corporation ("Masimo" or the "Company") (NASDAQ:MASI), today sent a letter to the Company's shareholders outlining why a majority of truly independent directors are urgently needed in the Masimo boardroom. Politan also released a detailed investor presentation m
SC 13G/A - NOVANTA INC (0001076930) (Subject)
SC 13G - NOVANTA INC (0001076930) (Subject)
SC 13G/A - NOVANTA INC (0001076930) (Subject)